Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2005-04-01
2009-11-17
Nickol, Gary B (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S350000, C530S402000, C530S412000, C435S069500
Reexamination Certificate
active
07619066
ABSTRACT:
The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation.
REFERENCES:
patent: 4935343 (1990-06-01), Allison et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5296592 (1994-03-01), Dower et al.
patent: 5319071 (1994-06-01), Dower et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5488032 (1996-01-01), Dower et al.
patent: 5492888 (1996-02-01), Dower et al.
patent: 5510462 (1996-04-01), Auron et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5591457 (1997-01-01), Bolton
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5980954 (1999-11-01), Bolton
patent: 5985657 (1999-11-01), Auron et al.
patent: 6020152 (2000-02-01), Tedder
patent: 6323311 (2001-11-01), Liu et al.
patent: 6416753 (2002-07-01), Yuan et al.
patent: 6511665 (2003-01-01), Dower et al.
patent: 6599873 (2003-07-01), Sommer et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 2005/0159590 (2005-07-01), Rotman et al.
patent: 0 502 956 (1997-04-01), None
patent: WO 92/11359 (1992-07-01), None
patent: WO 94/06457 (1994-03-01), None
patent: WO 96/23067 (1996-08-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 98/08969 (1998-03-01), None
patent: WO 99/36541 (1999-07-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 01/02571 (2001-01-01), None
patent: WO 01/02571 (2001-01-01), None
patent: WO 01/19390 (2001-03-01), None
patent: WO 01/25435 (2001-04-01), None
patent: WO 01/25435 (2001-04-01), None
patent: WO 02/36152 (2002-05-01), None
patent: WO 02/062375 (2002-08-01), None
patent: WO 2004/022718 (2004-03-01), None
patent: WO 2004/022718 (2004-03-01), None
Matsushime et al., Blood, 1991, 78:616-623.
Bottomley et al., “The citrate ion increases the conformational stability of α1-antitrypsin,”Biochem. Biophys. Acta, 1481:11-17 (2000).
Chen et al., “Strategies to suppress aggregation of recombinant keratinocyte growth factor during liquid formulation development,”J. Pharm. Sci., 83:1657-1661 (1994).
Dower et al., “The interleukin-1 receptor,”Immunology Today, 8(2):46-51 (1987).
Evans et al., “Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1β by site-directed mutagenesis,”J. Biol. Chem., 270:11477-11483 (1995).
Gallivan et al., “Cation-π interactions in structural biology,”Proc. Natl. Acad. Sci. USA, 96:9459-9464 (1999).
MacLean et al., “Stabilization of proteins by low molecular weight multi-ions,”J. Pharm. Sci., 91:2220-2229 (2002).
Schreuder et al., “Refined crystal structure of the interleukin-1 receptor antagonist,”Eur. J. Biochem., 227: 838-847 (1995).
Sims et al., “Cloning the interleukin 1 receptor from human T cells,”Proc. Natl. Acad. Sci. USA, 86:8946-8950 (1989).
Smith at al., “A single amino acid difference between human and monkey interleukin (IL)-1β dictates effective binding to soluble type II IL-1 receptor,”J. Biol. Chem., 277:47619-47625 (2002).
van den Burg et al., “Selection of mutations for increased protein stability,”Curr. Opin. Biotech., 13:333-337 (2002).
Vigers et al., “X-ray structure of interleukin-1 receptor antagonist at 2.0 Å resolution,”J. Biol. Chem., 269:12874-12879 (1994).
Vigers et al., “Crystal structure of the type-I Interleukin-1 receptor complexed with Interleukin-1β,”Nature, 368:190-194 (1997).
Chang et al., “Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist,”Pharmaceutical Research, 13:243-249(1996).
Chang et al., “Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation,”Archives of Biochemistry and Biophysics, 331:249-258 (1996).
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated May 9, 2006, for Application No. PCT/US2005/011332.
Kerwin Bruce
Raibekas Andrei
Amgen Inc.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Nickol Gary B
Xie Xiaozhen
LandOfFree
IL-1ra variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-1ra variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-1ra variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070297